Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.41 |
| ▸ | CCND1 | P24385 | 1/20 | 0.41 |
| ▸ | CCND2 | P30279 | 1/20 | 0.41 |
| ▸ | CCND3 | P30281 | 1/20 | 0.41 |
| ▸ | TNK2 | Q07912 | 15/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | STK4 | Q13043 | 1/20 | 0.38 |
| ▸ | STK3 | Q13188 | 1/20 | 0.38 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.38 |
| ▸ | STK26 | Q9P289 | 1/20 | 0.38 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.38 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041503 | 0.94 | TNK2 (0.43) | TNK2SRC | |
| SCHEMBL15036043 | 0.85 | JAK2 (0.46) | CDK4CCND1CCND2CCND3TNK2 | |
| SCHEMBL16309176 | 0.82 | TNK2 (0.40) | CDK4CCND1TNK2SRC | |
| SCHEMBL15036002 | 0.81 | TNK2 (0.42) | CDK4CCND1TNK2SRC | |
| SCHEMBL15041656 | 0.79 | TNK2 (0.41) | CDK4TNK2SRC | |
| SCHEMBL15036067 | 0.75 | TNK2 (0.41) | CDK4CCND1CCND2CCND3TNK2 | |
| SCHEMBL15036084 | 0.75 | TNK2 (0.43) | CDK4CCND1CCND2CCND3TNK2 | |
| SCHEMBL15036151 | 0.74 | PAK4 (0.50) | TNK2SRC | |
| SCHEMBL13553497 | 0.74 | CDK4 (0.38) | CDK4CCND1CCND2CCND3TNK2 | |
| SCHEMBL15041701 | 0.74 | SRC (0.38) | CDK4CCND1TNK2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912203-B2 | 6-(sulfonylaryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS HOLDINGS, INC. (US) | 2014-12-16 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CDK4 404/4885CCND1 2153/4885CCND2 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.